Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator's choice in relapsed/refractory mantle cell lymphoma

被引：0

作者：

Trneny, Marek

Lamy, Thierry

Walewski, Jan Andrzej

Belada, David

Mayer, Jiri

Radford, John A.

Jurczak, Wojciech

Morschhauser, Franck

Alexeeva, Julia

Rule, Simon

Biyukov, Tsvetan Nikolov

Patturajan, Meera

Bravo, Marie-Laure Casadebaig

Cabecadas, Jose

Arcaini, Luca

机构：

[1] Charles Univ Hosp, Dept Hematol, Prague, Czech Republic

[2] Hop Pontchaillou, Dept Hematol, Rennes, France

[3] Maria Sklodowska Curie Mem Inst & Oncol Ctr, Dept Lymphoid Malignancies, Warsaw, Poland

[4] Charles Univ Hosp & Fac Med, Dept Internal Med Hematol 4, Hradec Kralove, Czech Republic

[5] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[6] Univ Manchester, Manchester, Lancs, England

[7] Christie NHS Fdn Trust, Manchester, Lancs, England

[8] Jagiellonian Univ, Dept Hematol, Krakow, Poland

[9] Ctr Hosp Univ Reg Lille, Lille, France

[10] Fed Med Res Ctr, St Petersburg, Russia

[11] Derriford Hosp, Dept Hematol, Plymouth PL6 8DH, Devon, England

[12] Celgene Sarl, Boudry, Switzerland

[13] Celgene Corp, Summit, NJ USA

[14] Inst Portugues Oncol Francisco Gentil, Serv Anat Patol, Lisbon, Portugal

[15] Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy

[16] Univ Pavia, Dept Mol Med, I-27100 Pavia, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8547

引用

页数：1

共 50 条

[1] Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
Arcaini, Luca
Lamy, Thierry
Walewski, Jan
Belada, David
Mayer, Jiri
Radford, John
Jurczak, Wojciech
Morschhauser, Franck
Alexeeva, Julia
Rule, Simon
Cabecadas, Jose
Campo, Elias
Pileri, Stefano A.
Biyukov, Tsvetan
Patturajan, Meera
Casadebaig Bravo, Marie-Laure
Trneny, Marek
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (02) : 224 - 235
[2] Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator's Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study
Trneny, Marek
Lamy, Thierry
Walewski, Jan
Jurczak, Wojciech
Belada, David
Mayer, Jiri
Radford, John
Alexeeva, Julia
Osmanov, Dzhelil
Biyukov, Tsvetan
Patturajan, Meera
Bravo, Marie-Laure Casadebaig
Arcaini, Luca
BLOOD, 2014, 124 (21)
[3] IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY
Trneny, M.
Lamy, T.
Walewski, J.
Belada, D.
Mayer, J.
Radford, J.
Jurczak, W.
Morschhauser, F.
Alexeeva, J.
Rule, S.
Biyukov, T.
Patturajan, M.
Bravo, M. L. Casadebaig
Arcaini, L.
HAEMATOLOGICA, 2015, 100 : 4 - 4
[4] QUALITY OF LIFE IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS TREATED WITH LENALIDOMIDE VS INVESTIGATOR'S CHOICE: MCL-002 (SPRINT) TRIAL
Rule, S.
Arcaini, L.
Walewski, J.
Skotnicki, A.
Belada, D.
Mayer, J.
Alexeeva, J.
Afanasyev, B.
Kuzmin, A.
Jurczak, W.
Kaplanov, K.
Voloshin, S.
Radford, J.
Le Gouill, S.
Biyukov, T.
Patturajan, M.
Casadebaig-Bravo, M. L.
Mahmoud, D.
Hu, X. H.
Trneny, M.
HAEMATOLOGICA, 2015, 100 : 147 - 147
[5] Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
Trneny, Marek
Lamy, Thierry
Walewski, Jan
Belada, David
Mayer, Jiri
Radford, John
Jurczak, Wojciech
Morschhauser, Franck
Alexeeva, Julia
Rule, Simon
Afanasyev, Boris
Kaplanov, Kamil
Thyss, Antoine
Kuzmin, Alexej
Voloshin, Sergey
Kuliczkowski, Kazimierz
Giza, Agnieszka
Milpied, Noel
Stelitano, Caterina
Marks, Reinhard
Truemper, Lorenz
Biyukov, Tsvetan
Patturajan, Meera
Bravo, Marie-Laure Casadebaig
Arcaini, Luca
LANCET ONCOLOGY, 2016, 17 (03): : 319 - 331
[6] MCL-002: UPDATED EFFICACY AND SAFETY RESULTS FOR LENALIDOMIDE VSINVESTIGATOR'S CHOICE MONOTHERAPY IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Arcaini, L.
Rule, S.
Lamy, T.
Walewski, J.
Belada, D.
Mayer, J.
Radford, J.
Jurczak, W.
Morschhauser, F.
Alexeeva, J.
Biyukov, T.
Patturajan, M.
Bravo, M. L. Casadebaig
Trneny, M.
HAEMATOLOGICA, 2016, 101 : 476 - 476
[7] Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial
Trneny, Marek
Lamy, Thierry
Walewski, Jan
Belada, David
Mayer, Jiri
Radford, John A.
Jurczak, Wojciech
Morschhauser, Franck
Alexeeva, Julia
Rule, Simon A.
Afanasyev, Boris V.
Kaplanov, Kamil
Thyss, Antoine
Kuzmin, Alexej
Voloshin, Sergey
Kuliczkowski, Kazimierz
Giza, Agnieszka
Milpied, Noel
Stelitano, Caterina
Marks, Reinhard
Trumper, Lorenz
Biyukov, Tsvetan
Barnett, Evelyn
Bravo, Marie-Laure Casadebaig
Arcaini, Luca
BLOOD, 2016, 128 (22)
[8] IMPACT OF STABLE DISEASE OR BETTER RESPONSES TO LENALIDOMIDE ON SURVIVAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: MCL-001 (EMERGE) AND MCL-002 (SPRINT) STUDIES
Goy, A.
Arcaini, L.
Williams, M. E.
Lamy, T.
Besisik, S. K.
Drach, J.
Ramchandren, R.
Witzig, T. E.
Fu, T.
Zhang, L.
Biyukov, T.
Barnett, E.
Bravo, M. L. Casadebaig
Trneny, M.
HAEMATOLOGICA, 2016, 101 : 477 - 477
[9] Lenalidomide in relapsed/refractory mantle cell lymphoma post-bortezomib: Subgroup analysis of the MCL-001 study
Williams, Michael E.
Goy, Andre
Sinha, Rajni
Besisik, Sevgi Kalayoglu
Drach, Johannes W.
Ramchandren, Rod
Zhang, Lei
Cicero, Sherri
Fu, Tommy
Witzig, Thomas E.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[10] A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501).
Morrison, V. A.
Jung, S.
Johnson, J. L.
Leonard, J.
Cheson, B. D.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 3 4 5 →